<div id="readability-page-1">04:01 PM EST, 11/07/2025 (MT Newswires) -- Health care stocks edged lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) was shedding 1%.In corporate news, Gilead Sciences (GILD) shares dropped 4.7% after the company said a phase 3 trial comparing its drug Trodelvy with chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer did not meet the primary endpoint of progression-free survival.Moderna (MRNA) continues to target cash breakeven in 2028, banking on its ongoing cost reductions and revenue growth from geographic expansion and new product launches, Morgan Stanley said in a Friday note. The firm maintained its equalweight rating on Moderna but adjusted its price target to $30 from $32. Moderna shares were up 0.1%.Globus Medical (GMED) can continue delivering cash flow and has the ability to compound profits higher, BofA Securities said in a Thursday note. BofA upgraded the stock to buy from neutral and raised its price target to $91 from $65. Globus shares surged 36%.Haemonetics ( HAE ) is adopting a more cautious guidance approach following a rebound in plasma collection volumes, BofA said Thursday in a report. BofA upgraded Haemonetics ( HAE ) to neutral from underperform and raised its price objective to $75 from $58. Haemonetics ( HAE ) shares rose 2.2%. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

MRNA

GILD

GMED

Health care stocks declined late Friday, with the NYSE Health Care Index down 0.1%. Gilead Sciences shares fell 4.7% after a trial for Trodelvy failed to meet its primary endpoint. Moderna aims for cash breakeven by 2028, with a price target adjustment to $30. Globus Medical was upgraded to buy, with shares surging 36%. Haemonetics was upgraded to neutral, with shares rising 2.2%.

Sector Update: Health Care Stocks Ease Late Afternoon